NKTR vs. ADCT, AVIR, OMER, MCRB, ASMB, CPIX, ALXO, PCRX, LLY, and JNJ
Should you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include ADC Therapeutics (ADCT), Atea Pharmaceuticals (AVIR), Omeros (OMER), Seres Therapeutics (MCRB), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), ALX Oncology (ALXO), Pacira BioSciences (PCRX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceutical preparations" industry.
ADC Therapeutics (NYSE:ADCT) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, community ranking, institutional ownership, analyst recommendations, profitability and media sentiment.
ADC Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, ADC Therapeutics had 3 more articles in the media than Nektar Therapeutics. MarketBeat recorded 6 mentions for ADC Therapeutics and 3 mentions for Nektar Therapeutics. ADC Therapeutics' average media sentiment score of 0.66 beat Nektar Therapeutics' score of 0.13 indicating that Nektar Therapeutics is being referred to more favorably in the news media.
ADC Therapeutics presently has a consensus target price of $7.25, indicating a potential upside of 111.37%. Nektar Therapeutics has a consensus target price of $3.50, indicating a potential upside of 175.59%. Given ADC Therapeutics' higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than ADC Therapeutics.
41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 4.1% of ADC Therapeutics shares are held by company insiders. Comparatively, 3.7% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Nektar Therapeutics has a net margin of -195.02% compared to Nektar Therapeutics' net margin of -330.17%. ADC Therapeutics' return on equity of -107.31% beat Nektar Therapeutics' return on equity.
Nektar Therapeutics received 575 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 70.61% of users gave Nektar Therapeutics an outperform vote while only 65.00% of users gave ADC Therapeutics an outperform vote.
ADC Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.
Summary
Nektar Therapeutics beats ADC Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Nektar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nektar Therapeutics Competitors List
Related Companies and Tools
